General AML

EHA 2019 | BCL-2 as a universal target in AML


At the 24th Congress of the European Hematology Association (EHA), Marina Konopleva from the University of Texas, Houston, US, talks about BCL-2 as a universal target in acute myeloid leukemia (AML).
Dr. Konopleva explains how BCL-2 has become a very important target in AML, specifically using the example of venetoclax, in combination with hypomethylating agents (HMAs), which was approved by the US Food & Drug Administration (FDA) prior to the completion of the phase III trial and became the standard of care in the US for the treatment of unfit elderly patients.